M&T Bank
ALNY icon

M&T Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

M&T Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Sell
7,865
-101
-1% -$34.4K 0.01% 534
2025
Q4 		$3.17M Buy
7,966
+1,164
+17% +$515K 0.01% 508
2025
Q3 		$3.1M Sell
6,802
-1,401
-17% -$570K 0.01% 477
2025
Q2 		$2.67M Buy
8,203
+335
+4% +$92.7K 0.01% 535
2025
Q1 		$2.12M Sell
7,868
-740
-9% -$190K 0.01% 593
2024
Q4 		$2.03M Sell
8,608
-37
-0.4% -$9.73K 0.01% 672
2024
Q3 		$2.38M Buy
8,645
+206
+2% +$53.6K 0.01% 620
2024
Q2 		$2.05M Buy
8,439
+2,013
+31% +$318K 0.01% 647
2024
Q1 		$960K Sell
6,426
-369
-5% -$61.6K ﹤0.01% 895
2023
Q4 		$1.3M Sell
6,795
-179
-3% -$30.5K ﹤0.01% 784
2023
Q3 		$1.24M Buy
6,974
+124
+2% +$23.7K ﹤0.01% 770
2023
Q2 		$1.3M Sell
6,850
-20
-0.3% -$3.96K ﹤0.01% 777
2023
Q1 		$1.38M Buy
6,870
+661
+11% +$139K 0.01% 752
2022
Q4 		$1.48M Sell
6,209
-423
-6% -$90.2K 0.01% 711
2022
Q3 		$1.33M Buy
6,632
+2,089
+46% +$398K 0.01% 726
2022
Q2 		$662K Sell
4,543
-119
-3% -$16.9K ﹤0.01% 905
2022
Q1 		$763K Buy
4,662
+1,075
+30% +$164K ﹤0.01% 841
2021
Q4 		$608K Buy
3,587
+15
+0.4% +$2.79K ﹤0.01% 941
2021
Q3 		$674K Buy
3,572
+15
+0.4% +$2.81K ﹤0.01% 876
2021
Q2 		$604K Sell
3,557
-120
-3% -$17.6K ﹤0.01% 940
2021
Q1 		$519K Sell
3,677
-130
-3% -$19.6K ﹤0.01% 980
2020
Q4 		$495K Sell
3,807
-99
-3% -$13.2K ﹤0.01% 1070
2020
Q3 		$569K Sell
3,906
-313
-7% -$44.5K ﹤0.01% 917
2020
Q2 		$626K Buy
4,219
+536
+15% +$72.3K ﹤0.01% 855
2020
Q1 		$402K Sell
3,683
-438
-11% -$50.6K ﹤0.01% 1001
2019
Q4 		$475K Sell
4,121
-712
-15% -$71K ﹤0.01% 871
2019
Q3 		$388K Buy
4,833
+157
+3% +$12.4K ﹤0.01% 1065
2019
Q2 		$339K Sell
4,676
-625
-12% -$48K ﹤0.01% 1158
2019
Q1 		$495K Sell
5,301
-4
-0.1% -$335 ﹤0.01% 969
2018
Q4 		$387K Buy
5,305
+188
+4% +$14.5K ﹤0.01% 1011
2018
Q3 		$448K Buy
5,117
+381
+8% +$38.3K ﹤0.01% 1044
2018
Q2 		$466K Buy
4,736
+523
+12% +$51.9K ﹤0.01% 1032
2018
Q1 		$502K Buy
4,213
+103
+3% +$13.3K ﹤0.01% 999
2017
Q4 		$522K Buy
4,110
+50
+1% +$6.28K ﹤0.01% 985
2017
Q3 		$477K Sell
4,060
-70
-2% -$5.97K ﹤0.01% 1002
2017
Q2 		$331K Buy
+4,130
New +$264K ﹤0.01% 1163
2016
Q4 		– Sell
-4,818
Closed -$326K – 1704
2016
Q3 		$326K Buy
+4,818
New +$340K ﹤0.01% 1242
2016
Q2 		– Sell
-4,896
Closed -$307K – 1696
2016
Q1 		$307K Sell
4,896
-3,187
-39% -$212K ﹤0.01% 1259
2015
Q4 		$761K Buy
8,083
+2,174
+37% +$202K 0.01% 907
2015
Q3 		$475K Sell
5,909
-3,625
-38% -$403K ﹤0.01% 1085
2015
Q2 		$1.14M Sell
9,534
-379
-4% -$45.3K 0.01% 832
2015
Q1 		$1.03M Sell
9,913
-13
-0.1% -$1.32K 0.01% 854
2014
Q4 		$962K Sell
9,926
-2,169
-18% -$201K 0.01% 877
2014
Q3 		$945K Buy
+12,095
New +$780K 0.01% 915

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

M&T Bank's ALNY Position: Q1 2026 in Review

M&T Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.3% in Q1 2026, selling an estimated $34.4K and leaving 7,865 shares worth $2.6M. The position accounts for 0.01% of the portfolio, ranked #534.

M&T Bank first reported a position in ALNY in Q3 2014 and has held it in 44 quarters since. The position peaked at $3.17M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • M&T Bank held 7,865 shares of Alnylam Pharmaceuticals worth $2.6M as of Q1 2026.
  • M&T Bank sold 101 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $34.4K.
  • Alnylam Pharmaceuticals made up 0.01% of M&T Bank's portfolio in Q1 2026, its #534 holding.
  • M&T Bank first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 44 quarters since.
  • M&T Bank's Alnylam Pharmaceuticals position peaked at $3.17M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.